The future of innovative robotic technologies and artificial intelligence (AI) in pharmacy and medicine is promising, with the potential to revolutionize various aspects of health care. These advances aim to increase efficiency, improve patient outcomes, and reduce costs while addressing pressing challenges such as personalized medicine and the need for more effective therapies. This review examines the major advances in robotics and AI in the pharmaceutical and medical fields, analyzing the advantages, obstacles, and potential implications for future health care. In addition, prominent organizations and research institutions leading the way in these technological advancements are highlighted, showcasing their pioneering efforts in creating and utilizing state-of-the-art robotic solutions in pharmacy and medicine. By thoroughly analyzing the current state of robotic technologies in health care and exploring the possibilities for further progress, this work aims to provide readers with a comprehensive understanding of the transformative power of robotics and AI in the evolution of the healthcare sector. Striking a balance between embracing technology and preserving the human touch, investing in R&D, and establishing regulatory frameworks within ethical guidelines will shape a future for robotics and AI systems. The future of pharmacy and medicine is in the seamless integration of robotics and AI systems to benefit patients and healthcare providers.

In the present paper, we report the synthesis, characterization, and biological evaluation as antifungal, antibacterial, antioxidant, and cytotoxic/anticancer agents of N-, S-, O-substituted-1,4-naphtho- and 2,5-bis(amino-substituted)-1,4-benzoquinone derivatives. In the synthesized compounds, antimicrobial activity at low concentrations against Escherichia coli B-906, Staphylococcus aureus 209-P, and Mycobacterium luteum B-917 bacteria and Candida tenuis VKM Y-70 and Aspergillus niger F-1119 fungi in comparison with controls was identified. 2-(N-Diphenylmethylpiperazin-1-yl)-3-chloro-1,4-naphthoquinone 9a was the most potent, with a minimum inhibitory concentration value of 3.9 µg/mL against test culture M. luteum. The synthesized compounds were screened for their antioxidant capacity using the cupric-reducing antioxidant capacity (CUPRAC) method. 2,2'-[1-(2-Aminoethyl)piperazin-1-yl]-3,3'-dichloro-bis(1,4-naphthoquinone) 10 showed the highest antioxidant capacity, with a 0.455 CUPRAC-trolox equivalent antioxidant capacity (TEAC) coefficient. Other parameters of antioxidant activity (scavenging effects on OH(·), O2(·－), and H2O2) of these compounds were also determined. The cytotoxic activity of the compounds was investigated by employing the sulforhodamine B cell viability assay against A549 (lung), MCF-7 (breast), DU145 (prostate), and HT-29 (colon) cancer cell lines. Compound 10 exhibited the most powerful cytotoxic activity at a concentration of 20 µM against all cell lines. In addition to the strongest antioxidant activity of compound 10, it also had lowest IC50 values (<3 µM), warranting further in vivo studies due to its anticancer activity.